Distinct Toxicity Profiles for Anti-BCMA Myeloma Therapies
CAR T cells directed against the B-cell maturation antigen (BCMA) are linked to systemic and neurological side effects, while the antibody teclistamab is associated with increased infection risk.
United States David Miklos Zimu Gong David Mikos Stanford University Cancer Center At Houston Methodist Hospital
Source: medscape.com